相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
Xiaolei Zhang et al.
CANCER RESEARCH (2013)
Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
Luana Casetti et al.
CANCER RESEARCH (2013)
Characterizing rapid, activity-linked conformational transitions in proteins via sub-second hydrogen deuterium exchange mass spectrometry
Diana Resetca et al.
FEBS JOURNAL (2013)
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model
Lucile Couronne et al.
HAEMATOLOGICA (2013)
Tumor-derived Mutations in the Gene Associated with Retinoid Interferon-induced Mortality (GRIM-19) Disrupt Its Anti-signal Transducer and Activator of Transcription 3 (STAT3) Activity and Promote Oncogenesis
Shreeram C. Nallar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma
Brent D. G. Page et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma
Yunbao Pan et al.
PLOS ONE (2013)
Measuring Dynamics in Weakly Structured Regions of Proteins Using Microfluidics-Enabled Subsecond H/D Exchange Mass Spectrometry
Tamanna Rob et al.
ANALYTICAL CHEMISTRY (2012)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Hanna L. M. Koskela et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Loss of Expression and Function of SOCS3 Is an Early Event in HNSCC: Altered Subcellular Localization as a Possible Mechanism Involved in Proliferation, Migration and Invasion
Carlos Rossa et al.
PLOS ONE (2012)
Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model
Bhuvanesh Dave et al.
PLOS ONE (2012)
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
Xiaolei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Role of STAT3 in transformation and drug resistance in CML
Rajesh R. Nair et al.
FRONTIERS IN ONCOLOGY (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain
Brent D. G. Page et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Wolfgang Warsch et al.
BLOOD (2011)
HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis
Zachary C. Hartman et al.
CANCER RESEARCH (2011)
Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules
Steven Fletcher et al.
CHEMMEDCHEM (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients
Sandrine Hayette et al.
LEUKEMIA RESEARCH (2011)
Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis
Michael A. Dengler et al.
PLOS ONE (2011)
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes
Xiaolei Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2010)
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
Shannon K. McWeeney et al.
BLOOD (2010)
Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner
Teodora Pene-Dumitrescu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
B. Fuh et al.
BRITISH JOURNAL OF CANCER (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Disruption of Transcriptionally Active Stat3 Dimers with Non-phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities
Steven Fletcher et al.
CHEMBIOCHEM (2009)
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
A. K. Samanta et al.
ONCOGENE (2009)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Nadine N. Bewry et al.
MOLECULAR CANCER THERAPEUTICS (2008)
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Mhairi Copland et al.
BLOOD (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies
R Farid et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth
FM Corvinus et al.
NEOPLASIA (2005)
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
H Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3
J Schust et al.
ANALYTICAL BIOCHEMISTRY (2004)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Transcription factors as targets for cancer therapy
JE Darnell
NATURE REVIEWS CANCER (2002)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity
IH Oh et al.
ONCOGENE (2002)
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia
J Kaeda et al.
ACTA HAEMATOLOGICA (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
